These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 15963264)

  • 1. Immune responses induced by intranasal imiquimod and implications for therapeutics in rhinovirus infections.
    Clejan S; Mandrea E; Pandrea IV; Dufour J; Japa S; Veazey RS
    J Cell Mol Med; 2005; 9(2):457-61. PubMed ID: 15963264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of genital warts with an immune-response modifier (imiquimod).
    Beutner KR; Spruance SL; Hougham AJ; Fox TL; Owens ML; Douglas JM
    J Am Acad Dermatol; 1998 Feb; 38(2 Pt 1):230-9. PubMed ID: 9486679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of female genital warts with an analog of imiquimod 2% in cream: a randomized, double-blind, placebo-controlled study.
    Syed TA; Ahmadpour OA; Ahmad SA; Ahmad SH
    J Dermatol; 1998 Jul; 25(7):429-33. PubMed ID: 9714974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus.
    Edwards L; Ferenczy A; Eron L; Baker D; Owens ML; Fox TL; Hougham AJ; Schmitt KA
    Arch Dermatol; 1998 Jan; 134(1):25-30. PubMed ID: 9449906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokine induction and modifying the immune response to human papilloma virus with imiquimod.
    Slade HB
    Eur J Dermatol; 1998; 8(7 Suppl):13-6; discussion 20-2. PubMed ID: 10387958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463.
    Imbertson LM; Beaurline JM; Couture AM; Gibson SJ; Smith RM; Miller RL; Reiter MJ; Wagner TL; Tomai MA
    J Invest Dermatol; 1998 May; 110(5):734-9. PubMed ID: 9579537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imiquimod in basal cell carcinoma: how does it work?
    Dummer R; Urosevic M; Kempf W; Hoek K; Hafner J; Burg G
    Br J Dermatol; 2003 Nov; 149 Suppl 66():57-8. PubMed ID: 14616353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of cytokines in cynomolgus monkeys by the immune response modifiers, imiquimod, S-27609 and S-28463.
    Wagner TL; Horton VL; Carlson GL; Myhre PE; Gibson SJ; Imbertson LM; Tomai MA
    Cytokine; 1997 Nov; 9(11):837-45. PubMed ID: 9367544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of recurrent HSV disease using imiquimod alone or combined with a glycoprotein vaccine.
    Harrison CJ; Miller RL; Bernstein DI
    Vaccine; 2001 Feb; 19(13-14):1820-6. PubMed ID: 11166907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Off-label indications for imiquimod.
    Ganjian S; Ourian AJ; Shamtoub G; Wu JJ; Murase JE
    Dermatol Online J; 2009 May; 15(5):4. PubMed ID: 19624982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Mechanisms of imiquimod indirect antiviral activity].
    Hober D; Ajram L; Chehadeh W; Lazrek M; Goffard A; Dewilde A; Wattré P
    Ann Biol Clin (Paris); 2005; 63(2):155-63. PubMed ID: 15771973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod.
    Gibson SJ; Lindh JM; Riter TR; Gleason RM; Rogers LM; Fuller AE; Oesterich JL; Gorden KB; Qiu X; McKane SW; Noelle RJ; Miller RL; Kedl RM; Fitzgerald-Bocarsly P; Tomai MA; Vasilakos JP
    Cell Immunol; 2002; 218(1-2):74-86. PubMed ID: 12470615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune response modification: imiquimod.
    Tyring S
    Australas J Dermatol; 1998 Nov; 39 Suppl 1():S11-3. PubMed ID: 9842095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokine induction by the immunomodulators imiquimod and S-27609.
    Testerman TL; Gerster JF; Imbertson LM; Reiter MJ; Miller RL; Gibson SJ; Wagner TL; Tomai MA
    J Leukoc Biol; 1995 Sep; 58(3):365-72. PubMed ID: 7665993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imiquimod in clinical practice.
    Edwards L
    Australas J Dermatol; 1998 Nov; 39 Suppl 1():S14-6. PubMed ID: 9842096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imiquimod treatment induces expression of opioid growth factor receptor: a novel tumor antigen induced by interferon-alpha?
    Urosevic M; Oberholzer PA; Maier T; Hafner J; Laine E; Slade H; Benninghoff B; Burg G; Dummer R
    Clin Cancer Res; 2004 Aug; 10(15):4959-70. PubMed ID: 15297396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imiquimod for anogenital warts in non-immunocompromised adults.
    Grillo-Ardila CF; Angel-Müller E; Salazar-Díaz LC; Gaitán HG; Ruiz-Parra AI; Lethaby A
    Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010389. PubMed ID: 25362229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical imiquimod: a review of its use in genital warts.
    Perry CM; Lamb HM
    Drugs; 1999 Aug; 58(2):375-90. PubMed ID: 10473026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imiquimod 5% cream: a topical immune response modifier.
    Marini M
    Int J Dermatol; 2002 May; 41 Suppl 1():1-2. PubMed ID: 12087812
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunomodulatory and pharmacologic properties of imiquimod.
    Sauder DN
    J Am Acad Dermatol; 2000 Jul; 43(1 Pt 2):S6-11. PubMed ID: 10861101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.